FDA Approves Rucaparib for BRCA Ovarian Cancer – Medscape
Medscape |
FDA Approves Rucaparib for BRCA Ovarian Cancer
Medscape The US Food and Drug Administration (FDA) today granted accelerated approval to the oral therapy rucaparib (Rubraca, Clovis Oncology) for the treatment of women with advanced ovarian cancer who have received two or more prior chemotherapies and … Clovis’s ovarian cancer drug wins accelerated FDA approval PARP Inhibitor Gets FDA Nod for Ovarian Cancer FDA grants accelerated approval to new treatment for advanced ovarian cancer |
View original article
Author:
Powered by WPeMatico